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ABSTRACT 
The drug ABT-335 (Fenofibricacid ) choline fenofibrate found to be useful in the treatment of dyslipidemia as compare with other fibrate. So the 
present investigation to developed mini-tablets to overcome the dose dumping problem by regular shape, uniformity, smooth surface excellent 
size and encapsulated in capsule to improve the efficacy and bioavailability of the drug. Different formulations were developed by 
utilizingcontrolling of the release rate and gel forming polymers like microcrystalline cellulose, hypromellose by dry granulation technique. 
Among all formulation SRM-3 having the drug release for longer period of time as compare to other formulation. SRM-3 was found to be stable 
during stability study for one month.  
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INTRODUCTION 
Controlled drug delivery technology suggests a quantitative 
comprehension of physicochemical mechanism of 
availability of drug to the sustained that dosage form release 
rate can be determined.Promising development and new 
strategy to oral controlled release drug delivery includes 
hydrodynamic pressure controlled system.The oral 
administration is considered because of its convenience of 
self-administration, compactness and easy 
manufacturing.1,2For controlled–release system, oral route of 
drug administration has attracted most attention. This is 
because there is more flexibility of dosing. 
The high level of cholesterol in the blood can raise a 
personchances for developing heart disease. Cholesterol has 
transported to the blood stream by carrier proteins known 
as lipoproteins. Low density lipoproteins (LDL) tend to 
deposit cholesterol-laden “plaques’ in artery walls, 
narrowing the opening through which blood flows and 
increasing the risk of heart disease. The LDL cholesterol has 
been dubbed the “Bed” cholesterol and high density 
lipoproteins (HDL) cholesterol is known as “good” 
cholesterol because HDL carries cholesterol to the liver. It is 
breakdown and remove from the blood it can wind upon 
artery walls. High blood level triglycerides, the body’s 
storage from of fat and a primary source of energy, are also 
associated with a great risk of heart disease.3-5 
Various synthetic preparations are available for dislipidemia 
like HMG-COA reductase inhibitors (statins), fibric acid 
derivatives (fibrates), clofibrate, gemfibrozil, tricor, lofibra. 
These conventional tablets are associated with an increased 
incidence of gallstones, myopathy, rhabdomyolysis, 
destruction of muscular tissue, gastrointestinal disturbances, 
headache, abdominal pain nausea, vomiting, constipation. 
Due to this, powerful strain drug, cerivastin (lipobay) and 
clofibrate was withdrawn because of this complication. To 
overcome the drawback of older fibrate to design the new 
ABT-335 (fenofibric acid) Choline fenofibrate sustained 
release tablet, particularly interm of pharmacokinetic 
properties. Which does not needed enzymatic cleavage to 
become active. It easily dissociates to active from free 
fenofibric acid and does not undergo fast pass hepatic 
metabolism. The fenofibric acid is well absorbed through out 
GIT and statistically increased bioavailability then other 
fibrate. 
The drug ABT-335 (fenofibric acid) choline fenofibrate found 
to be useful in the treatment of dyslipidaemia as compared 
with other fibrates.  For controlled drug delivery system, oral 
route of administration has attracted most attention. This is 
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because there is more flexibility of dosing. The design of the 
matrix tablet to overcome the problem of dose dumping by 
excellent size uniformity, shape and smooth surface and this 
also improve the bioavailability and efficacy of the drug. 
MATERIALS AND METHODS 
Choline fenofibrate was obtained as gift sample from Aristo 
pharmaceutical, Bhopal, M.P, India. Microcrystalline 
cellulose, Hypromellose, polyvinaylpyrolidone, colloidal 
silicon dioxide and Sodium stearyl fumarate were procured 
from Aristo Pharmaceutical pvt Ltd, Bhopal, M.P, India.. All 
other chemicals and ingredients used for study were of 
analytical grade. 
 
Preparation of Sustained Release Matrix Tablet: 
Choline fenofibrate, Hypromelloseand microcrystalline 
cellulose through sieve 30 and mix properly.Take 20 ml of 
purified water in a beaker and add polyvinyl pyrolidone to it 
under stirring to dissolve. Granulate the contents of step 1 
with binder solution of step 2 in a stainless still bowl. Dry the 
wet mass in a rapid dryer with an inlet temperature of 50-
550Cfor 10-15 minutes. Pass the dried granules through 
sieve no20 and collect in a tight container. Pass the colloidal 
silicon dioxide through sieve no 40 and mix with dried 
granules for 3 minutes. Pass sodium stearyl fumarate 
through sieve no 60 and mix with sample. Compress the 
blend using 2.90mm multi-tip punch standard concave and 
plain on both side and note the parameters.6 
 
Table 1: Formulation of Choline Fenofibrate Matrix Tablet 
Ingradients Formulations 
SRM1 SRM 2 SRM 3 
Choline fenofibrate 178.83 178.83 178.83 
Microcrystalline cellulose 75.26 62.57 54.99 
Hypromellose 10.0 20.0 30.0 
Polyvinyl pyrolidone 2.69 2.69 2.69 
Colloidal silicon dioxide 0.53 0.53 0.53 
Sodium lauryl fumarate 2.69 5.38 5.38 
 
Characterization of Sustained Release Tablet: 
The granulation blends of sustained release tablet are 
compressed into tablets by using 2.90mm multi-tip punch 
standard concave and plain on both sides on a tablet 
machine (SHIMO Machinary). All batches are prepared 
tablets were evaluated employing following parameter like 
weight variation, hardness, friability test and drug content. 
Weight Variation:7 
Twenty tablets were individually weighed and then their 
average weight was calculated. The average weight was 
com[pared with the individual tablets weight and the weight 
variation was calculated. The weight of a tablet should be 
within acceptable limits as it is an important property that 
influence the amount of drug present in it.  
Hardness:7 
The tablet requiredcertain amount of strength of hardness 
and resistance to friability, to withstand mechanical shocks 
while handling, packaging or transportation. The hardness of 
the prepared tablet was determined by using Monsanto 
hardness tester. For each batch five tablets were tested and 
average was calculated. 
Friability:7 
The tablet were weighted and introduced into friability 
apparatus (Electrolab) the apparatus was operated for 100 
revolutions. The tablets were then removed, dusted and 
percentage friability was calculated using following formula 
% friability = {1-(Wt -/W)} × 100 
Where, W = Initial weight of tablets 
Wt  = Weight of tablets after 100 revolution. 
Drug content:8 
Content of 10 capsules (120 tablets) were weighted and 
finely powdered, accurately powder of 12 tablets, 
transferred in a 10 ml volumetric flask and dissolve in 10 ml 
phosphate buffer and filtered it and observed the reading in 
UV. The results were mentioned in the table. 
Dissolution Study:9, 10-11 
A single capsule was placed in a vessel. Fastened to the 
bottom of the shift. Connected to a variable speed of motors. 
The vessels were filled with the dissolution medium (6.8 
phosphate buffer) and the temperature were maintained at 
37 ±0.5 C using a constant temperature bath.The shaft is 
adjusted to turn at the specified speed and the sample of the 
fluid are withdrawn at intervals to determine the amount of 
drug in solution. At same time add equal amount of fresh 
medium into the dissolution vessels.  
RESULTS AND DISCUSSION 
Charecterization of sustained release tablet: 
Various micromeritics properties were performed on bland. 
The angle of repose was found to be 340, tapped density was 
0.57, bulk density was 0.46, compressibility index was 13.72, 
Hausner’s ratio was 1.15. All parameter was found to be in 
range. The formulation sustained release matrix tablet was 
optimized by trial and error method. Three batches were 
designed by using different amount of hyoermellose and 
sodium steryll fumarate to overcome the problem of sticking. 
The tablets were prepared and characterised. 
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Micrimeritics properties are given below: 
Table 2: Micromeritics properties of choline fenofibrate 
Parameter 
 
Parameter 
SRM-01 SRM-02 SRM-03 
Bulk Density 0.462 0.44 0.46 
Tapped Density 0.57 0.56 0.57 
Compressibility Index (%) 15.09 13.20 13.72 
Hausners ratio 1.16 1.15 1.15 
Loss on drying 3.11 3.10 3.11 
Angle of repose 31 33 34 
 
All the formulations were evaluated for weight variation, 
hardness, thickness, friability and % drug content. The 
tablets tested were found to have acceptable limit (±55%) of 
weight variation and therefore passes the test. The results 
were recorded in table. The hardness was to be found to be 
within the design input values as desired i.e. 5kg/cm2. The 
results are recorded in table 2. The friability of tablets was 
found to be within acceptable limits, i.e. less than 1% as 
specified USP. 
  
Table 3: Characterization of formulated sustained release tablet of choline fenofibrate 
Formulation Code Weight (mg) % weight variation Hardness (Kps) Friability (%) Drug Content (%) 
SRM-01 22.62 1.90 3.2 0.46 98.29 
SRM-02 22.54 1.64 2.8 0.32 97.82 
SRM-03 22.6 1.98 3.0 0.54 99.29 
 
The formulated sustained release tablets passed the weight 
variation and friability tests and the variations were within 
the permitted limits. 
The release profile was observed in 6.8 phosphate buffer. 
The excellent release profile was found in the batch SRM-03, 
in which hypromellose and sodium steryl fumarate in a 
higher amount as compare to other batches. It was found 
that the developed product was not only long acting but safe 
effective as well. 
 
Table 4: Correlation between dissolution data of all three batches 
Time (hr) Cumulative % drug release 
SRM-01 SRM-02 SRM-03 
1 13.86±1.73 20.30±2.55 21.83±0.55 
2 26.05±1.22 35.15±3.99 38.64±0.63 
4 45.52±1.37 57.914±2.44 76.80±0.93 
6 58.50±1.79 68.48±1.53 90.84±0.65 
8 68.61±1.33 77.26±2.81 95.37±0.97 
10 91.08±1.95 96.00±2.40 96.70±0.49 
12 95.40±1.77 96.06±3.42 98.07±0.57 
 
 
 
Figure 1: Drug Release profile of Matrix tablet 
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Among all three dissolution data, the dissolution data of 
SRM-03 was found to be excellent release profile (98%) as 
compared to the other two batches (SRM-01 & SRM-02).In 
which hypromellose and sodium stearyl fumarate in a higher 
as compare to other batches. It was found that the developed 
product was not only long acting but safe and effective as 
well.  
Stability studies were carried out of the most satisfactory 
formulation F1, at 30 ± 2°C / 65 ± 5% RH and 40 ± 2°C / 75 ± 
5% RH for two months to assess their long term stability as 
per ICH guidelines. At various time intervals of 30 days and 
60 days, samples were evaluated. There was no major 
change in the various physicochemical parameters evaluated 
like hardness, drug content, in-vitro dissolution pattern at 
the various sampling points. There was no statistically 
significant difference between the initial values and the 
results obtained during stability study.  
CONCLUSION 
Fibrates are used to relieve from the hyperlipidemia by 
reducing the cholesterol level. In the present study it was 
developed a sustained release matrix delivery of ABT-335 
(Fenofibric acid) choline Fenofibrate, which has high 
capacity of lipolysis and elimination of triglycerides rich 
particle from plasma. SRM-03 was found to be excellent 
release profile (98%) as compared to the other two batches 
(SRM-01 & SRM-02).   In which hypromellose and sodium 
stearyl fumarate in a higher as compare to other batches. 
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